These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 24903965

  • 21. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML.
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [Abstract] [Full Text] [Related]

  • 22. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E.
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [Abstract] [Full Text] [Related]

  • 23. Associations of serum sclerostin and polymorphisms in the SOST gene with bone mineral density and markers of bone metabolism in postmenopausal Chinese women.
    He J, Zhang H, Wang C, Zhang Z, Yue H, Hu W, Gu J, Fu W, Hu Y, Li M, Liu Y, Zheng H, Zhang Z.
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E665-73. PubMed ID: 24423318
    [Abstract] [Full Text] [Related]

  • 24. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
    Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, Cristol JP.
    Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
    [Abstract] [Full Text] [Related]

  • 25. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, Peris P.
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [Abstract] [Full Text] [Related]

  • 26. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [Abstract] [Full Text] [Related]

  • 27. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
    Peng J, Dong Z, Hui Z, Aifei W, Lianfu D, Youjia X.
    BMC Musculoskelet Disord; 2021 May 25; 22(1):480. PubMed ID: 34034718
    [Abstract] [Full Text] [Related]

  • 28. Sclerostin and Dickkopf-1 in renal osteodystrophy.
    Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH.
    Clin J Am Soc Nephrol; 2011 Apr 25; 6(4):877-82. PubMed ID: 21164019
    [Abstract] [Full Text] [Related]

  • 29. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group.
    J Bone Miner Res; 2006 Aug 25; 21(8):1215-23. PubMed ID: 16869719
    [Abstract] [Full Text] [Related]

  • 30. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
    Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE.
    Diab Vasc Dis Res; 2014 Jan 25; 11(1):48-52. PubMed ID: 24227537
    [Abstract] [Full Text] [Related]

  • 31. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II.
    Osteoporos Int; 2013 Aug 25; 24(8):2191-9. PubMed ID: 23358608
    [Abstract] [Full Text] [Related]

  • 32. Investigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitus.
    Kurban S, Selver Eklioglu B, Selver MB.
    J Pediatr Endocrinol Metab; 2022 May 25; 35(5):673-679. PubMed ID: 35411762
    [Abstract] [Full Text] [Related]

  • 33. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G.
    Calcif Tissue Int; 2012 Jun 25; 90(6):473-80. PubMed ID: 22527202
    [Abstract] [Full Text] [Related]

  • 34. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.
    J Clin Endocrinol Metab; 2018 Apr 01; 103(4):1302-1309. PubMed ID: 29365099
    [Abstract] [Full Text] [Related]

  • 35. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
    Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, Vray M, Steinberg G, Roux C.
    Joint Bone Spine; 2015 Mar 01; 82(2):109-15. PubMed ID: 25557658
    [Abstract] [Full Text] [Related]

  • 36. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
    Hooshmand S, Brisco JR, Arjmandi BH.
    Br J Nutr; 2014 Jul 14; 112(1):55-60. PubMed ID: 24780728
    [Abstract] [Full Text] [Related]

  • 37. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.
    Simpson CA, Foer D, Lee GS, Bihuniak J, Sun B, Sullivan R, Belsky J, Insogna KL.
    Osteoporos Int; 2014 Oct 14; 25(10):2383-8. PubMed ID: 24927689
    [Abstract] [Full Text] [Related]

  • 38. Role of sclerostin in the bone loss of postmenopausal chinese women with type 2 diabetes.
    Zhou YJ, Li A, Song YL, Zhou H, Li Y, Tang YS.
    Chin Med Sci J; 2013 Sep 14; 28(3):135-9. PubMed ID: 24074614
    [Abstract] [Full Text] [Related]

  • 39. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women.
    Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E.
    Clin Endocrinol (Oxf); 2012 Jun 14; 76(6):797-801. PubMed ID: 22151063
    [Abstract] [Full Text] [Related]

  • 40. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.
    Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S.
    J Clin Endocrinol Metab; 2010 Nov 14; 95(11):5056-62. PubMed ID: 20631014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.